These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 7897379

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.
    Zuckerman JN, Kirkpatrick CT, Huang M.
    J Travel Med; 1998 Mar; 5(1):18-22. PubMed ID: 9772311
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later.
    Briem H, Safary A.
    J Med Virol; 1994 Dec; 44(4):443-5. PubMed ID: 7897378
    [Abstract] [Full Text] [Related]

  • 5. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine.
    Maiwald H, Jilg W, Bock HL, Löscher T, Sonnenburg F.
    Vaccine; 1997 Mar; 15(4):346-8. PubMed ID: 9141202
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Reactivity and immunogenicity of Havrix 360 vaccine for hepatitis A].
    Borcić B, Kovac S, Mihaljević I, Dobrovsak-Sourek V, Ljubicić M.
    Lijec Vjesn; 1996 Mar; 118(7-8):162-4. PubMed ID: 8965633
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years.
    Fan PC, Chang MH, Lee PI, Safary A, Lee CY.
    Vaccine; 1998 Mar; 16(2-3):232-5. PubMed ID: 9607035
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination.
    Totos G, Gizaris V, Papaevangelou G.
    Vaccine; 1997 Aug; 15(11):1252-3. PubMed ID: 9286052
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.
    Theilmann L, Kallinowski B, Gmelin K, Hofmann F, Scheiermann N, Wohland B, Stickl H, Maiwald H, Moriabadi FK, Bock HL.
    Vaccine; 1992 Aug; 10 Suppl 1():S132-4. PubMed ID: 1335644
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K, Ibánez I, Perret C, Vial P, Zinsou JA.
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study.
    Goilav C, Zuckerman J, Lafrenz M, Vidor E, Lauwers S, Ratheau C, Benichou G, Zuckerman A.
    J Med Virol; 1995 Jul; 46(3):287-92. PubMed ID: 7561805
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults.
    Bruguera M, Bayas JM, Vilella A, Tural C, González A, Vidal J, Dal-Ré R, Salleras L.
    Vaccine; 1996 Oct; 14(15):1407-11. PubMed ID: 8994314
    [Abstract] [Full Text] [Related]

  • 18. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization.
    Zaaijer HL, Leentvaar-Kuijpers A, Rotman H, Lelie PN.
    J Med Virol; 1993 May; 40(1):22-7. PubMed ID: 8515245
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.